P&G Consumer Health

2024 Words9 Pages
Procter & Gamble 2. Portfolio Analysis and Strategy Execution 2.1 What are the key challenges and opportunities that present in each of P&G’s portfolios? 2.1.2 In Consumer Health- Nesh Introduction on P&G’s Consumer Health Procter and Gamble has a 1.3% value share (peak was at 1.7% in 2006) in Consumer Health Segment. P&Gs largest consumer health category is over the counter (OTC), in which it derives most sales from cough, cold and allergy remedies and digestive remedies. It also has presence in herbal/traditional products, vitamins and dietary supplements (VDS), child-specific consumer health oral care and feminine hygiene. It has no meaningful presence in weight management, sports nutrition or allergy care. P&G suffers from pressure due to competitors’ launch of prescription to OTC launches, private label/cheaper brands and legislative issues in US, which is its key market. While it has lost share in that area, it has been driving up sales for its VDS, herbal/traditional products and child-specific consumer health. It also has been divesting prescription drugs due to lack of growth and market demand. Most its R&D and marketing investments also remain in oral care while ignoring OTC and other categories. Source: Euromonitor Health Care net sales increased 5% to $12 billion on 5% growth in unit volume. Volume increased high single digits in developing regions and low single digits in developed regions. Breakdown in the categories as follows: Oral Care grew mid-single digits behind initiative activity and incremental merchandising support of Crest and Oral-B. Global market share of the oral care category was up over half a point. Personal Health Care grew low

More about P&G Consumer Health

Open Document